Elsamitrucin  (Synonyms: BMY-28090; SPI-28090; Antibiotic BBM 2478A)

Elsamitrucin, derived from actinomycete fermentation, exhibits potent cytotoxicity against a range of murine and human tumor cell lines in vitro, with IC₅₀ values ranging from <0.02 to 3.25 μg/ml after 72-hour exposures. In vivo studies demonstrated significant antitumor activity in various experimental murine tumor models, including P388 leukemia, L1210 leukemia, B16 melanoma, and M5076 sarcoma, when administered intraperitoneally as a water-insoluble free base or as water-soluble lactate or succinate salts. Elsamitrucin also showed efficacy against human MX-1 mammary tumor and HCT116 colon tumor xenografts, highlighting its broad-spectrum cytotoxicity and potential as an antitumor agent across different tumor types and models^[1].

653.63

C₃₃H₃₅NO₁₃

97068-30-9

C[C@H]1O[C@@H](OC2=C3C(C(O)=C(C(OC4=C5C6=C(C)C=C4)=O)C5=C3OC6=O)=CC=C2)[C@H](O[C@@]7([H])O[C@H](C)[C@H](O)[C@H](OC)[C@H]7N)[C@](O)(C)[C@H]1O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Experimental antitumor activity of BMY-28090, a new antitumor antibiotic